PFE Quote, Financials, Valuation and Earnings

Arvinas has a net margin of 2.31% compared to Pfizer's net margin of -76.18%. Pfizer's return on equity of 8.91% beat Arvinas's return on equity of -32.96%.

Pfizer has a consensus price target of $31.32, signalling upside risk potential of 19.56%. On the other hand Arvinas has an analysts' consensus of $43.32 which suggests that it could grow by 403.09%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Arvinas has a beta of 1.954, suggesting its more volatile than the S&P 500 by 95.435%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.47%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $17.8B, which are larger than Arvinas quarterly revenues of $59.2M. Pfizer's net income of $410M is higher than Arvinas's net income of -$45.1M. Notably, Pfizer's price-to-earnings ratio is 18.54x while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.34x versus 2.35x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 2.31% compared to Pfizer's net margin of 23.56%. Pfizer's return on equity of 8.91% beat Gilead Sciences's return on equity of 2.5%.

Pfizer has a consensus price target of $31.32, signalling upside risk potential of 19.56%. On the other hand Gilead Sciences has an analysts' consensus of $111.26 which suggests that it could grow by 4.23%. Given that Pfizer has higher upside potential than Gilead Sciences, analysts believe Pfizer is more attractive than Gilead Sciences.

Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.47%. Gilead Sciences offers a yield of 2.9% to investors and pays a quarterly dividend of $0.79 per share. Pfizer pays 118.44% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Pfizer quarterly revenues are $17.8B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Pfizer's net income of $410M is lower than Gilead Sciences's net income of $1.8B. Notably, Pfizer's price-to-earnings ratio is 18.54x while Gilead Sciences's PE ratio is 288.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.34x versus 4.67x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 2.31% compared to Pfizer's net margin of -117.16%. Pfizer's return on equity of 8.91% beat Moderna's return on equity of -29.09%.

Pfizer has a consensus price target of $31.32, signalling upside risk potential of 19.56%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 56.4%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.47%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $17.8B, which are larger than Moderna quarterly revenues of $956M. Pfizer's net income of $410M is higher than Moderna's net income of -$1.1B. Notably, Pfizer's price-to-earnings ratio is 18.54x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.34x versus 4.14x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 2.31% compared to Pfizer's net margin of 24.22%. Pfizer's return on equity of 8.91% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Pfizer has a consensus price target of $31.32, signalling upside risk potential of 19.56%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 39.64%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.47%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Pfizer pays 118.44% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Pfizer quarterly revenues are $17.8B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Pfizer's net income of $410M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Pfizer's price-to-earnings ratio is 18.54x while Regeneron Pharmaceuticals's PE ratio is 17.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.34x versus 5.36x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.